Market briefs: Gateley; Cyprotex

NEWLY-listed commercial law firm Gateley said in a pre-close statement that its full-year results will show revenue growth of 10% to more than £60m.

The firm, which has an office in Manchester, listed on AIM in June and will publish its full-year figures for the year to April 30 on September 15.

In a brief statement the firm said: “The board is pleased to announce that the business continued to perform well in the second half of its financial year. Revenues in the second half continued to demonstrate strong fee income growth and demand for Gateley’s services.”

Chief executive Michael Ward said: “We are encouraged to report such a strong trading statement, our first as a public company.  Post-admission to AIM, Gateley continues to trade very well and we look to the future with confidence.”

::

CHESHIRE-based Cyprotex, the specialist contract research organisation that works with major pharmaceutical companies,  has launched a biosciences division to complement its existing ADME-Tox business.

The firm which has offices in Macclesfield and also at Alderley Park, said the new division allows customers to access its expertise in 2D and 3D cell-based efficacy screening to investigate the therapeutic or biological effect of new molecules.

Chief executive Dr Anthony Baxter said: “Introducing a Biosciences division is a natural progression from ADME-Tox, allowing us to further diversify our business without significant investment, and enabling us to expand into a new customer base.”